title: Hereditary hyperphosphatasia: 20 year follow-up and response to disodium etidronate.
abstract: We provide a 20 year follow-up of a family with three siblings affected by hereditary hyperphosphatasia (HH). An iliac crest bone biopsy was performed on one of the siblings following double-tetracycline labeling, with results reported quantitatively in a standard histomorphometric format. Biochemical parameters of disease activity were monitored in the patient before and after treatment with oral etidronate disodium, 20 mg/kg/day taken for 5 weeks. Biochemical evidence of intense disease activity continued 20 years after the initial diagnosis of HH in the sibling studied. His bone biopsy specimen also revealed extremely high bone turnover but low cancellous bone volume and osteoclasts unlike those found in Paget's disease. Treatment with etidronate disodium resulted in a temporary 40% reduction in serum alkaline phosphatase and 24 h urine hydroxyproline excretion, with reduction in serum osteocalcin from two times the upper limit of normal to a subnormal level. We conclude that disease activity in HH can continue unabated for two decades. Our bone biopsy finding of low cancellous bone volume, the consistent lack of pagetic-looking osteoclasts in our and other studies, plus the clinical features of HH (childhood onset and extremely diffuse disease with gross skeletal deformation) serve to distinguish HH from Paget's disease. Bisphosphonates may be of value in treating HH.
authors.affiliation: Department of Medicine, College of Physicians and Surgeons, Columbia University, New York, New York.
authors.forename: F
authors.initials: F
authors.lastname: Singer
authors.forename: E
authors.initials: E
authors.lastname: Siris
authors.forename: E
authors.initials: E
authors.lastname: Shane
authors.forename: D
authors.initials: D
authors.lastname: Dempster
authors.forename: R
authors.initials: R
authors.lastname: Lindsay
authors.forename: M
authors.initials: M
authors.lastname: Parisien
mesh_terms: D000328:Adult; D000469:Alkaline Phosphatase / Q000097:blood*; D001842:Bone and Bones / Q000473:pathology*; D012968:Etidronic Acid / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D005190:Family; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D006909:Hydroxyproline / Q000652:urine; D007085:Ilium / Q000473:pathology; D008297:Male; D010001:Osteitis Deformans / Q000188:drug therapy* / Q000235:genetics / Q000473:pathology; D015675:Osteocalcin / Q000097:blood; D011859:Radiography; D011884:Radius / Q000000981:diagnostic imaging / Q000473:pathology; D014457:Ulna / Q000000981:diagnostic imaging / Q000473:pathology
chemical_list: D015675:Osteocalcin; D000469:Alkaline Phosphatase; D012968:Etidronic Acid; D006909:Hydroxyproline